Synopsis
Lars Fruergaard Jørgensen, the CEO of Novo Nordisk, the world’s largest producer of insulins, shares his thoughts on how to arrest the growing numbers of diabetes patients; the company’s blockbuster weight-loss drug Wegovy; regulating medicine prices; and more.
For Lars Fruergaard Jørgensen, CEO, Novo Nordisk, the world’s largest producer of insulins, India is a crucial market, amid the worrying uptrend in the reported number of cases of diabetics and pre-diabetics. Besides making medical treatment available and imparting training to nurses, he says, it is important that people in big cities change the way they live. From meals to giving up a sedentary lifestyle, everything needs to be reviewed
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
